Real-life experience with sorafenib for advanced and refractory desmoid-type fibromatosis.

Delphine SchampersAlexander Decruyenaere Jacobs Celine Lore D F Lapeire

Published in: Acta oncologica (Stockholm, Sweden) (2024)

Real-life data on the use of sorafenib in the treatment of DF is consistent with published data in clinical trial setting. Sorafenib is an effective treatment option for progressive DF although associated with significant toxicity and the need for rapid dose reduction.

Keyphrases

clinical trial
electronic health record
multiple sclerosis
oxidative stress
randomized controlled trial
systematic review
combination therapy
data analysis
smoking cessation
quantum dots
meta analyses